OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study.

@article{Hanifin2016OPA15406AN,
  title={OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study.},
  author={Jon M. Hanifin and Charles N. Ellis and Ilona J Frieden and Regina Foelster-Holst and Linda F Stein Gold and Angelo Secci and Angela J Smith and Cathy Xinghua Zhao and Elena Kornyeyeva and Lawrence F Eichenfield},
  journal={Journal of the American Academy of Dermatology},
  year={2016},
  volume={75 2},
  pages={
          297-305
        }
}
BACKGROUND Peripheral leukocytes in patients with atopic dermatitis (AD) have elevated phosphodiesterase-4 activity, which is associated with production of proinflammatory mediators. OPA-15406 is a phosphodiesterase-4 inhibitor with high selectivity for phosphodiesterase-4-B. OBJECTIVES We sought to assess effectiveness and tolerability of topical OPA-15406 in patients with AD. METHODS This was a randomized, double-blind, vehicle-controlled, phase-II study. Patients 10 to 70 years of age… CONTINUE READING
Highly Cited
This paper has 36 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Clinical approach to the patient with refractory atopic dermatitis.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology • 2018

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Management of Itch in Atopic Dermatitis.

American journal of clinical dermatology • 2018
View 1 Excerpt

Atopic dermatitis: an overview.

American family physician • 2012
View 1 Excerpt